These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22586841)

  • 1. Synthetic biology in the view of European public funding organisations.
    Pei L; Gaisser S; Schmidt M
    Public Underst Sci; 2012 Feb; 21(2):149-62. PubMed ID: 22586841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public-private partnership models in France and in Europe.
    Demotes-Mainard J; Canet E; Segard L
    Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research funding: Reform oversight of Italy's science funds.
    Carafoli E; Montecucco C
    Nature; 2016 May; 533(7602):179. PubMed ID: 27172036
    [No Abstract]   [Full Text] [Related]  

  • 4. Why French politics and science don't mix.
    Nat Mater; 2004 May; 3(5):275. PubMed ID: 15122212
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tinkering initiative biology: policies and issues of Do-it-yourself biology].
    Meyer M
    Med Sci (Paris); 2013 May; 29 Spec No 2():36-7; discussion 38-40. PubMed ID: 23759494
    [No Abstract]   [Full Text] [Related]  

  • 6. Securing funds for health promotion: lessons from health promotion foundations based on experiences from Austria, Australia, Germany, Hungary and Switzerland.
    Schang LK; Czabanowska KM; Lin V
    Health Promot Int; 2012 Jun; 27(2):295-305. PubMed ID: 21467099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Principles of planning and financing scientific work at the research institutes of the Ministry of Public Health of the Ukrainian SSR under new management conditions].
    Pasechnik SI
    Vrach Delo; 1989 Dec; (12):1-4. PubMed ID: 2697967
    [No Abstract]   [Full Text] [Related]  

  • 8. The potential of synthetic biology: a view from the European Academies Science Advisory Council.
    Fears R; ter Meulen V
    Nat Rev Microbiol; 2011 Mar; 9(3):222. PubMed ID: 21326277
    [No Abstract]   [Full Text] [Related]  

  • 9. What strategy should France implement for H2020?
    Dhainaut JF; Diebolt V; Pouletty-Lefèbvre B; ; Baker A; Bassompierre F; Borel T; Braunstein D; Demotes J; François B; Huet S; Micallef J; Misse C; Molon A; Rascol O; Ravoire S; Schwartz B; Donne N; Donne N; Fusaï G; Pouletty P; Vicaut E
    Therapie; 2015; 70(1):95-109. PubMed ID: 25747841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rare diseases. Funding programs in Germany and Europe].
    Wetterauer B; Schuster R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):519-28. PubMed ID: 18425694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Union to fund mutant mouse archive for genomics research.
    Weber W
    Lancet; 2001 Jun; 357(9272):1957. PubMed ID: 11425434
    [No Abstract]   [Full Text] [Related]  

  • 12. Competitive funding and structures for public health research in European countries.
    McCarthy M; Conceição C; Grimaud O; Katreniakova Z; Saliba A; Sammut M; Narkauskaité L
    Eur J Public Health; 2013 Nov; 23 Suppl 2():39-42. PubMed ID: 24189795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic biology and the prospects for responsible innovation.
    Macnaghten P; Owen R; Jackson R
    Essays Biochem; 2016 Nov; 60(4):347-355. PubMed ID: 27903822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research funding of university medicine by the BMBF, DFG, and EU].
    Adler G; von dem Knesebeck J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Sep; 52(9):917-24. PubMed ID: 19693474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Funding for public health in Europe in decline?
    Rechel B
    Health Policy; 2019 Jan; 123(1):21-26. PubMed ID: 30509874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIHR to simplify open-funding programs.
    Vogel L
    CMAJ; 2013 Nov; 185(17):1484. PubMed ID: 24130234
    [No Abstract]   [Full Text] [Related]  

  • 17. Ethical, legal, and social issues (ELSI) in rare diseases: a landscape analysis from funders.
    Hartman AL; Hechtelt Jonker A; Parisi MA; Julkowska D; Lockhart N; Isasi R
    Eur J Hum Genet; 2020 Feb; 28(2):174-181. PubMed ID: 31537898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
    Kelly R; Zoubiane G; Walsh D; Ward R; Goossens H
    Lancet Infect Dis; 2016 Apr; 16(4):431-40. PubMed ID: 26708524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diversity of regulation and public financing of IVF in Europe and its impact on utilization.
    Berg Brigham K; Cadier B; Chevreul K
    Hum Reprod; 2013 Mar; 28(3):666-75. PubMed ID: 23223400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the European cancer research landscape: An evidence base for national and Pan-European research and funding.
    Begum M; Lewison G; Lawler M; Sullivan R
    Eur J Cancer; 2018 Sep; 100():75-84. PubMed ID: 30014883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.